Publications by authors named "M Comert"
Hypogammaglobulinemia in a Child with Clericuzio-Type Poikiloderma with Neutropenia.
Pediatr Allergy Immunol Pulmonol
December 2024
Article Synopsis
- Poikiloderma with neutropenia (PN) is a rare genetic condition resulting from mutations in a specific gene, characterized by skin changes, ongoing low neutrophil levels, and recurrent respiratory infections.
- A case study of a 15-month-old boy revealed symptoms like skin hyperpigmentation, growth issues, and respiratory infections, with notable physical traits such as facial dysmorphism and widespread poikiloderma.
- Laboratory tests indicated mild neutropenia and low immunoglobulin levels, leading to treatment with immunoglobulin replacement and antibiotics, highlighting the importance of monitoring immune function in patients with recurrent infections.
BCR::ABL1-negative myeloproliferative neoplasms (MPNs) pose a substantial risk of thrombosis, leading to significant morbidity and mortality. Anticoagulant therapy, historically based on vitamin K antagonists (VKAs), has limitations in preventing recurrent thrombotic events and managing bleeding complications. Direct oral anticoagulants (DOACs) offer a potential alternative with improved pharmacokinetics and compliance.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated a method to test for beta-lactam antibiotic (BLA) allergies in children with a history of low-risk non-immediate reactions (NIR) using a direct single therapeutic dose challenge followed by a prolonged drug provocation test (DPT).
- A total of 109 children participated, with most reporting a reaction to amoxicillin-clavulanic acid; the most common symptom observed was maculopapular exanthema.
- Results indicated that an initial single-dose DPT was safe and effective, with only a small percentage experiencing minor reactions, suggesting this approach can help identify true allergies in children.
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis.
Materials And Methods: Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of the pPCL diagnosis, 20% leukocytes or ≥2x10/L plasma cells in the peripheral blood was used as a diagnostic criterion.
Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant.
Int J Hematol Oncol Stem Cell Res
July 2024
Graft Versus Host Disease (GvHD), which can be observed at a rate of 30-80% after allogeneic stem cell transplantation (ASCT) is an important complication that adversely affects the survival and quality of the life of patientsPosttransplant cyclophosphamide (PTCy) effectively prevents GvHD after HLA-haploidentical ASCT. In our study, the use of PTCy in 1-antigen HLA-mismatched unrelated donor (9/10MMUD) ASCT was compared with standard GvHD prophylaxis in HLA-identical related donor (MRD) ASCT. We conducted a retrospective study of the comparison of 42 patients with 9/10 MMUD ASCT receiving PTCy+Methotrexate (MTX)+Calcineurin Inhibitor (CNI) and 37 patients with HLA-identical MRD who received MTX+CNI in 3 bone marrow transplantation centers.
View Article and Find Full Text PDF